Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

FDA approves Novo Nordisk’s weight loss drug Wegovy for reducing cardiovascular risk

The Food and Drug Administration has given the green light to Novo Nordisk’s highly anticipated weight loss drug, Wegovy, for reducing the risk of serious cardiovascular complications in adults with obesity and heart disease. This move could potentially expand insurance coverage for the drug and similar treatments for obesity, addressing a major barrier to patient access.

Wegovy, along with its diabetes counterpart Ozempic, has caused a stir in the weight loss industry due to their effectiveness in helping patients shed pounds. The FDA’s approval of Wegovy to mitigate the risk of heart-related issues marks a significant milestone, highlighting the broader health benefits of weight loss medications beyond just managing weight and blood sugar levels.

According to a landmark late-stage trial, weekly injections of Wegovy have been shown to reduce the overall risk of heart attack, stroke, and cardiovascular-related death by 20%. This expanded approval positions Wegovy as the first-ever weight loss medication with such a designation, signaling a major advancement in public health for adults with obesity and heart disease.

The FDA emphasized that Wegovy should be used in conjunction with a reduced calorie diet and increased physical activity to maximize its benefits. Both Wegovy and Ozempic, which belong to a class of drugs that mimic a gut hormone to suppress appetite, have seen a surge in demand and experienced shortages over the past year. However, their high cost, approximately $1,000 per month before insurance, has been a limiting factor for many patients.

Novo Nordisk hailed the FDA’s approval as a pivotal step in addressing critical health concerns, indicating a positive trajectory in the ongoing battle against obesity and its associated cardiovascular risks.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *